Harmony Biosciences Holdings HRMY 深 沪
已收盘 08-15 16:00:00 美东时间
36.87
+0.360
+0.99%
华盛通- 最 高36.95
- 今 开36.48
- 成交量 45.06万股
- 最 低 36.15
- 昨 收 36.51
- 总市值 21.21亿
- 52周最高 41.61
- 市盈率 静 14.67
- 换手率 0.78%
- 52周最低 26.47
- 委 比 32.78%
- 总股本 5753.26万
- 历史最高 62.085
- 量 比 1.00
- 振 幅 2.19%
- 历史最低 18.6112
- 每 手 1
- 风险率 3.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Preview For Liquidia
Liquidia (NASDAQ:LQDA) is gearing up to announce its quarterly earnings on Tues...
08-11 23:04
Harmony Biosciences Holdings shares are trading lower after the company reported a Q2 sales miss.
Harmony Biosciences Holdings shares are trading lower after the company reporte...
08-05 20:22
Harmony Biosciences Hldgs Affirms FY2025 Sales Guidance of $820.000M-$860.000M vs $841.400M Est
Harmony Biosciences Hldgs (NASDAQ:HRMY) affirms FY2025 sales outlook from $820.000 million-$860.000 million to $820.000 million-$860.000 million vs $841.400 million estimate.
08-05 19:31
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
What's Next: Ocular Therapeutix's Earnings Preview
Ocular Therapeutix (NASDAQ:OCUL) will release its quarterly earnings report on ...
08-05 04:04
Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study
Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability across all doses.
07-22 01:29
美股大行评级 | 巴克莱上调 Robinhood目标价至102美元；瑞银下调京东目标价从58美元至50美元
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从25美元升至29美元；摩根士丹利：维持Legend Biotech"超配"评级，目标价从80美元升至81美元
07-11 09:04
Deutsche Bank Maintains Buy on Harmony Biosciences Hldgs, Raises Price Target to $55
Deutsche Bank analyst David Hoang maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and raises the price target from $54 to $55.
07-11 02:17
Harmony Biosciences Reveals Promising Preclinical Data for BP1.15205
Harmony Biosciences Holdings ( ($HRMY) ) just unveiled an update. On June 11, 2...
06-11 20:47
Harmony Biosciences, Lupin reach agreement on Wakix generic launch
Lupin can launch a generic version of Harmony Biosciences' (NASDAQ:HRMY) Wakix (pitolisant) in January 2030 under a settlement agreement. The agreement resolves patent infringement litigation filed by...
06-05 22:54
